title: Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
abstract: A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy. Two years later C-erbB2-positive IBC was diagnosed in the right breast, and was treated with mastectomy and radiotherapy. Two years later skin metastases appeared, and trastuzumab was started initially as monotherapy, and later with paclitaxel and capecitabine. More than 12 years after diagnosis and 7 years after trastuzumab was started, the patient remains in complete clinical remission on trastuzumab and capecitabine.
authors.affiliation: Servicio de Farmacia Hospitalaria, Hospital Universitario de Guadalajara, Guadalajara, Spain.
authors.forename: Alicia
authors.initials: A
authors.lastname: Lázaro
authors.forename: Javier
authors.initials: J
authors.lastname: Casinello
authors.forename: Almudena
authors.initials: A
authors.lastname: Amorós
authors.forename: Miriam
authors.initials: M
authors.lastname: Heredia
authors.forename: Ana
authors.initials: A
authors.lastname: López-Alfonso
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000069287:Capecitabine; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D002945:Cisplatin / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D008408:Mastectomy; D016609:Neoplasms, Second Primary; D017239:Paclitaxel / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D015996:Survival Rate; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069287:Capecitabine; D002945:Cisplatin; D003841:Deoxycytidine; D005472:Fluorouracil; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab
references.citation: Cochrane Database Syst Rev. 2004;(2):CD003374
references.pmid: 15106201
references.citation: Oncology (Williston Park). 2004 Dec;18(14 Suppl 12):32-6
references.pmid: 15685824
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
references.pmid: 10716719
references.citation: Clin Breast Cancer. 2001 Oct;2(3):190-208; discussion 209
references.pmid: 11899413
references.citation: Eur J Cancer. 1994;30A(7):921-7
references.pmid: 7946584
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: J Clin Oncol. 2007 Aug 1;25(22):3246-50
references.pmid: 17577021
references.citation: Breast Cancer Res. 2000;2(6):423-9
references.pmid: 11250736
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Cancer. 1998 Jun 15;82(12):2366-72
references.pmid: 9635529
references.citation: Breast Cancer Res Treat. 2003;79 Suppl 1:S11-8
references.pmid: 12868801